LUCIUS 卢修斯 阿达格拉西布 Adagrasib非小细胞肺癌

阿达格拉西布

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Adagrasib

老挝国家食药监局批准上市
老挝国家药检所检测认证

Fach film-bons

Each film-coated tablet contains

非小细胞肺癌

Adagrasib ...................

LUCIUS

Indication:

PHARMACEUTICALS

LuciAda is an inhibitor of the RAS GTPas
Tamily indicated for the treatment of adult
patients with KRAS G12C-mutated locally
advanced or metastatic non-small cell lun

LuciAlda

cancer (NSCLC), as determined by an
approved test, who have received at least
ned by an FDÅ-

stemic therapy.

Adagrasib Tablets

* Kecommended dosage: 600 mg orally
twice daily.
.Swallow tablets whole with or without

200mg

FDA批准

food.

Morage: in a dry place and store at 20℃ to

Rx only

Warning:
Keep medicine out of reach of Children. Do
not administered LuciAda in Pregnancy an
Lactation patient treatment.
PLEASE SEE PACKAGE INSERT
Manufactured and Marketed by

LUCIUS

权威认证

Thonemang village, Xaythany district
Vientiane Capital, Laos
www.lucius.la

Warning: To be sold by retail on nreserintion
of registered physicians only, and as directed
by the physician

90 Tablets

口碑质量

适应症:
阿达格拉西布是RAS GTPase抑制剂,适用于治疗KRAS
G12C突变的局部晚期或转移性非小细胞肺癌癌症
(NSCLC)的成年患者:这些患者之前至少接受过一次全
身治疗。
推荐剂量:
1、口服给药,每次600mg,每日两次;
2、整片吞下,随或不随食物均可。